RxDoctor Payments DataLook up a doctor →

Iftikhar Hussain, MD

Allergy & Immunology · Tulsa, OKNPI 1205854015

Payments from drug & device makers

$7,129,563in general payments, 2019–2025

Across 2,559 payments — averaging $2786.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2.6M
  • AbbVie$615K
  • Eli Lilly$557K
  • GSK$544K
  • Sanofi US Services Inc.$389K
  • Novartis$310K
  • plus $2.1M from 54 others
$58,311in research payments, 2019–2025

Across 108 payments — averaging $539.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$27K
  • Regeneron$23K
  • GSK$3K
  • Sanofi US Services Inc.$3K
  • AbbVie$2K
  • Insmed, Inc.$2K

What the payments were for

  • Consulting fees$25,79214%
  • Speaking & faculty fees$103,16454%
  • Travel & lodging$31,84017%
  • Food & beverage$29,22515%
  • Education$3760%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer487$2,565,934
AbbVie(2 entities)177$614,630
Eli Lilly33$557,248
GSK179$543,787
Sanofi US Services Inc.80$389,356
Novartis66$310,332
LEO Pharma AS43$250,663
Grifols Therapeutics LLC17$213,011
Genentech, Inc.49$199,065
AstraZeneca195$197,240
Optinose US, Inc.109$155,500
Hikma Pharmaceuticals USA10$109,230
Vanda Pharmaceuticals Inc.24$108,948
Incyte Corporation154$100,401
Bristol Myers Squibb20$90,597
Roche Products Limited18$81,512
Takeda Pharmaceuticals U.S.A., Inc.53$68,724
Grifols Biologicals LLC14$64,025
Teva Pharmaceuticals USA, Inc.25$44,021
CSL Behring134$40,748
Cipla USA Inc.18$40,192
Kedrion Biopharma, Inc.14$38,931
VYNE Pharmaceuticals Inc.18$38,746
Regeneron34$37,829
Astrazeneca AB4$35,940
Adare Pharmaceuticals, Inc.10$35,798
Lilly USA, LLC80$32,873
Biohaven Pharmaceutical Holding Company Ltd.26$26,421
Astrazeneca UK Limited4$26,100
Sanofi87$16,390
Insmed, Inc.18$14,753
Janssen Research & Development, LLC2$12,672
Modernatx, Inc.6$9,500
Dermira, Inc.1$8,958
Genentech USA, Inc.54$8,584
Grifols USA, LLC58$7,674
Shire North American Group Inc17$6,571
Alk-abello, Inc9$6,423
F. Hoffmann-la Roche AG8$5,629
Gilead1$3,500
Merck9$2,841
Blueprint Medicines Corporation17$2,003
LEO Pharma Inc.6$1,907
Johnson & Johnson(2 entities)54$1,137
Regeneron Healthcare Solutions, Inc.40$1,056
Amgen14$515
Kaleo, Inc.20$324
Sanofi-aventis U.S. LLC9$322
Galderma Laboratories, L.p.5$181
Sunovion Pharmaceuticals Inc.4$131
Daiichi Sankyo Inc.3$126
ADMA Biomanufacturing LLC4$124
Boehringer Ingelheim1$122
ARS Pharmaceuticals Operations, Inc.3$68
Electromed, Inc.4$62
Greer Laboratories, Inc.2$39
Pharming Healthcare, Inc.2$38
Biocryst US Sales Co., LLC2$35
Organon1$30
Mylan Specialty L.p.1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy & immunology providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$563,844
Medicare patients
128
Services billed
17,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab46$178,269
SpravatoEsketamine Hcl25$124,701
XolairOmalizumab12$20,341
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$19,654
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$11,295
SymbicortBudesonide/Formoterol Fumarate42$10,088
Breo ElliptaFluticasone/Vilanterol19$7,715
Epinephrine26$4,243
Montelukast Sodium123$1,775
Albuterol Sulfate HfaAlbuterol Sulfate51$1,323
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,079
Ventolin HfaAlbuterol Sulfate16$875
Doxepin Hcl17$513
Azelastine Hcl14$424
Fluticasone Propionate29$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$1,137$124,70125 claims
GSKTrelegy Ellipta, Breo Ellipta$543,787$27,36842 claims
AstraZenecaBreztri Aerosphere, Symbicort$197,240$21,38353 claims
Genentech, Inc.Xolair$199,065$20,34112 claims
Hikma Pharmaceuticals USAEpinephrine$109,230$4,24326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other allergy & immunology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →